 He also helped establish the World Marrow Donor Association in 1990, and served (at various different times) as the president of the International Society for Experimental Haematology, the European Group for Blood and Marrow Transplantation, the European Haematology Association and several other medical and scientific organisations.From the late 1990s onwards, Goldman was instrumental in promoting the use of the anti-cancer drug imatinib, working to refine and expand its clinical usage as a targeted therapy.He retired from Hammersmith Hospital in 2004, but continued to work as an advocate and benefactor of cancer research and treatment in the developing world.